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donedurfngbaseline,duringisoproterenolinfusion(0.15@kg/rein)anddur-
ing acuteLVfailureby coronarymicroambdization.Resufts:Alongthe LV
inflowtracttherawasanearfydiastolicpositivegradient(PLVmitral-PLVapex)




The PLVmitral-PLVapexcorrelatedwith peak mitral-to-apicalflow velocity
(r= 0.67, p < 0.05),and the PLVapex-PLVsubaottacorrelatedwith peak
apax-subaortaflowvelocities(r= 0.82,p < 0.05).
Baseline Failure Iamxoterenol
PLVmifral-PLVapex(mmHg) 1.6+ l.1# 1.0 * o.7~ 2.6 A2,1#*
PLVapex-PLVsubsorta(mmHg) 3.5 i l.o# 1.5 * log’ 3.9 * 1.4#
‘p <0.05 when comparingIoealpressures:*p <0.05 vs baseline.
Conclusion:This etudyshowsthe existenceof differentintraventricular
diastolicpreseuregradientsin the LVinflowandoutflowtract.Thegradients
andflowvelocitiesweremodifiedbychangeain inotropyandiaehemia.













the relationshipbetweenbodymass,raceand HTNin patients(pts)with
symptomaticCHF (NYHAClass2.8 + 0.8, mean* SD) in a prospective
etudyof 557ptswithreducedLVejectionfraction(LVEF),meanLVEF25%
+ 13%.Prfmatyetiologyof HTNCMwaeaseignadonly after exclusion,of
otheretiologiesand meetingourcriteriafor HTN:a) currentor previousan-
tihypeflenaivepharmacologictherapyor b) documentationof systolicblood
preesure(SBP)readingof ?140 mmHgor diastolic(DBP)290 mmHgon 3
separateoeeaeaiona.WefoundAfrieen-Amerieane(Ms) morelikelyto have
HTNastheprimatycardiomyopathyetiologythanCaucasians(Cc),75%va
25%,p <0.001 butno racialdifferencewaeeeenin ptshavinga historyof
HTNand anotherCHFprimaryetiology(2ndHTN),46%vs 52%,p = NS.
HTNCMptawereolderat presentationthanthe other2 groupscombined,
(54+12 yra.ve50 + 14yra.,p = 0.02)and hadhigherbaselineLVEF(28
+ 13%ve24 + 12%,p e 0.01).Asexpecled,HTNCMptshadhigherreating
SBPandDBPthan2ndHTNptsorin ptswithnoHTN(SBP:135+ 23mmHg
va 121+20 mmHgvs 111+ 17mmHg,p c 0.01;DBP:87 & 15mmHgvs
78 + 14 mmHgve72 + 12 mmHg,p < 0.01).Althoughno differencewas
seenin heightbetweenthe3 groups,(172A 11cmvs 172+ 10cmvs 173
+ 10cm,p = NS)HTNCMptaweremoreobesethanptswith2nd HTNor
ptawithnoHTN(89+ 24kgve79+ 20kgvs75+ 18kg,p < 0.01)resulting
in HTNCMptahavinggreaterbodymassindex(k@-f~)than2ndHTNptsor
ptawithnoHTN(30A 7VS27 + 7 VS25i 5, p c 0.01).Usingmulticategory











Qualityof life is importantin the evaluationof congestiveheartfailure.To
analyzequalityof life in AfricanAmerieens(AA),the MedicalOutcomes
Study (SF-36) and the Minnesota Living with Heart Failure (LlhFE) question-
naires were administered to 114AA patients with congestive heart failure by
NHANES criteria, (46 men, age 64 + 17 yrs.; 88 women, age 84 + 11yre.).
Mean ecoresforthe LlhFE wefe physical dimension 16, emotional dimension
5 total 31. All scores were mmparable to norms for patients treated for CHF
in earlier studies.
SF-36Scaies Male Female GrouP Norms
Phvsicslfunctioning 50,91 33.64* 40.55 47.54
Ro~e/physical - 56.52 43.16**
SodiiyPain
49.32 34.37
74.05 61.15” 66.31 62.67
Generai Hesith 55.73 49,48 51s8 47.05
VitalHy 52s)5 42.5* 46,32 44.29
Soeislfunctioning 77.27 69.S7 72.S4 71.31
Role-Emotional 75,19 77.95 76.85 63.67
Mental Health 74.S2 70.15 72.04 74.6s
*p< 0.05 msle vs female: “’p= 0.06
Stepwise linear regression analysis identified 3 of 16 variables, angina,
income and treatment with one of three CHF drugs, ae predietora of quality
of life. These data suggest that in AA with CHF, men have higher aelf-
assessmentof theirphysicalfunctionand vitalitythanwomen,but aaaeaa-
mentof social functioning, emotional, mental and general health is aimilar
in men and women. In AA with CHF, phyeical and emotional role function ie
maintained at a higher Ievei than in other groups with CHF, but overall quality
of life ia not significantly lower.
m930157 Cachexiaaa IndependentPredictorof SurvivalinHeartFailure




Cardiaccachexiais long recognised,but little investigated.We soughtto
determine,whetherthecachacficstateinchronicheartfailure(CHF)providea
additionalprognosticinformationforall-causemortali~.BetweenJune1993
and May1995we aesessedin 167consecutiveCHFpatienta(16 female)
treadmillexercisecapacity(peakV02 17.5+ 6.8 ml/kgJmin,mean+ SD)
andfunctionalslatus(NYHA1:n = 21, H:59, Ill: 88, IV:19,LVEF30 & 15%
(n= 114),age61 +10 y).Cachexiawasprospectivelydefinedon the basis
of a non-intentionaldocumentedweightlossof > i’.s~o of previous normal
weight (n = 28, range 9-36%, i.e. 6-30 kg) in >6 months,
Resu/ts:Censoring the follow-up in June 1996,38 patients had died after
a mean of 238 + 221 d (follow-up of survivors 676 + 197 d). The cachactic
state was predictive of survival independently of age, NYHA class, LVEFand
peak VO.Z.The mortaiity in the cacheetic cohort was 18% at 3 montha (me),
32% at 6 mo; 39% at 12 mo, and 50% at 18 mo. Patients with a peak V02
< 14 ml/kgfmin (respective mortality 17, 28, 38, and 43Yo) and defined ae
cachectic had a l-year suwival of 38% (18 mo: 23%), compared to 96% (18
mo: 91%), in patients with neither of these two risk faetore (both p < 0.0001).
Cone/usion:Theeachectic state is an independent risk factor of eurvival in
CHF.Combined with alowpeak VOpit identifies an extremely high-risk aubset
of CHF patients. Its assessment should be included in transplant aaaesement
programmed and intewention studies that aim at survival analyses.
ml lmmunocWokine~odulationpWdic@Adver*
ClinicalOutcomeInAdvancedHeattFailure
F.S.Malik, M.R. Mehra, A. Ali, H.O. Ventura, M.A. Wingard, D.D. Stapleton,
A.K. Pridjian, F.W.Smart. OchsnerMedicalInstitutions,NewOrfeane,LA,
USA
Immurtocytokine(IC)activationhas beenimplicatedin the progressionof
chronicheartfailure(HF).Thesolubleformof ICAM-I (sICAM-1)iselevated
inHFandeorreiateewithdieeaseseverity.Theprognosticvalueofmodulation
of circulatingalCAM-1in mneatl with neurohormonai factors, during raeov-
ery from daeompensatad heart failure has not bean hitherto investigated. We






of therapy. Patienta were evaluated at study end and Day 7 of therapy by
the six-minute walk test. Results:Nine patients demonatratad improvement
in functional class [NYHA 2.7, Group 1], whiie 5 patients failed to improve
[NYHA 4, Group 2]. Comparisons of hemodynamica, immunoeytokine and
neurohormonal changea in the two groups are shown in the table.
Only increase in sICAM-I and peraistant Etp release at the end of therapy
